ангиотензин IV 不会在体内产生前血栓性作用
Qifang Wu1,2,3,4, Christine Gille1,2,3, Florian Maderspacher1,2,3
1Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.
Journal of molecular and cellular cardiology plus
|March 3, 2025
概括
ангиотензин IV (AngIV) 似乎没有促进血凝块的形成. 研究发现AngIV没有增加血栓形成或影响血小板聚合,这表明它不调节关键的前血栓机制.
科学领域:
- 心血管生物学 心血管生物学
- 血液静止和血栓形成
- 脏生理学 脏生理学
背景情况:
- 血栓形成是与心血管疾病相关的死亡的主要原因.
- 氨酸- ангиотензин系统的调节失调有助于发生血栓事件.
- ангиотензинII (AngII) 促进血小板聚合,但其他 ангиотензин,如 ангиотензинIV (AngIV) 在血栓形成中的作用尚不清楚.
研究的目的:
- 为了研究angiotensin IV (AngIV) 的潜在原血栓性作用.
- 探索AngIV介导的血栓形成中的机制.
主要方法:
- 连续给予AngIV小鼠4周使用透式迷你.
- 评估血栓形成,血小板计数和血小板聚合.
- 对心脏HGF,c-MET或PAI-1表达水平的测量.
- 在体外测试人类血小板聚合与HGF.
主要成果:
- AngIV治疗没有诱导心脏中的血栓形成.
- 血小板数量和聚合不受AngIV的影响.
- 在心脏中没有观察到HGF,c-MET或PAI-1表达的变化.
- 人类血小板聚合在与HGF.化时保持不变.
结论:
- ангиотензин IV (AngIV) 在小鼠中没有表现出前列血栓性作用.
- AngIV似乎无法调节血栓形成的关键机制,包括血小板聚合和特定基因表达.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
363
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
363
Antihypertensive Drugs: Direct Renin Inhibitors
468
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
468
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
447
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
447
Antihypertensive Drugs: Angiotensin II Receptor Blockers
568
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
568
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
123
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
123
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
753
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
753


